{
  "report_rows": [
    {
      "kpi": "2Q26 adjusted diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$7.62 vs. cons $7.47",
      "confidence": "HIGH"
    },
    {
      "kpi": "2Q26 revenue",
      "prediction": "BEAT",
      "answer": "pred ~$20.23B vs. cons $19.43B",
      "confidence": "HIGH"
    },
    {
      "kpi": "2Q26 adjusted EBITDA",
      "prediction": "BEAT",
      "answer": "pred ~$4.03B vs. cons $3.95B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 adjusted diluted EPS guidance",
      "prediction": "LOWER",
      "answer": "guide ~$29.60 vs. cons $30.30 (FY26)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY26 adjusted EBITDA guidance",
      "prediction": "LOWER",
      "answer": "guide ~$15.75B vs. cons $15.95B (FY26)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY26 revenue guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$78.25B vs. cons $78.20B (FY26)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 health-insurance-exchange pre-tax headwind assumption",
      "prediction": "LOWER",
      "answer": "guide ~($1.10B) vs. cons ~($1.00B) (FY26)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 1.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -1.5,
  "day5_path": "FADE",
  "day5_rationale": "Day-1 relief is likely if final 2Q26 results remain near the preannounced ~$7.62 EPS and ~$4.03B EBITDA, but FY26 EPS guidance of roughly $29.60 versus ~$30.30 consensus leaves out-period earnings math lower; continued exchange-headwind uncertainty and weak surgery mix should drive further estimate reductions.",
  "day5_confidence": "MEDIUM"
}